Abstract
Treatment of BOV places a high burden on healthcare resources such as hospitalizations. It was estimated that there were approximately 20,000 new cases of BOV in the Philippines every year. Vasoactive agents such as terlipressin, somatostatin, and sandostatin are widely used for the treatment of BOV. The objective of our analysis was to quantify the budget impact of using terlipressin for treating BOV patients from the Philippines health system perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
